Transcription factor Egr-1 in cardiovascular biology;Transkripční faktor Egr-1 v kardiovaskulární biologii

Casopis Lekaru Ceskych

Volumn 146, Issue 5, 2007, Pages 466-473

  Kunes P ^a,b   Krejsek, J ^a  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b Ústav Klinické Imunologie a Alergologie LF UK a FN ^*  (Czech Republic)

Author keywords

Apoptosis; Atherosclerosis; DNA; Egr 1; Genetic information; Transcription factor; Zinc fingers

Indexed keywords

EARLY GROWTH RESPONSE FACTOR 1;

ANIMAL; APOPTOSIS; ATHEROSCLEROSIS; BLOOD RHEOLOGY; HUMAN; HYPERTENSION; INFLAMMATION; ISCHEMIA; LIPID METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY; REVIEW;

ANIMALS; APOPTOSIS; ATHEROSCLEROSIS; EARLY GROWTH RESPONSE PROTEIN 1; HEMORHEOLOGY; HUMANS; HYPERTENSION; INFLAMMATION; ISCHEMIA; LIPID METABOLISM;

EID: 34249312978     PISSN: 00087335     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Ludewig, B., Krebs, P., Scandella, E.: Immunopathogenesis of atherosclerosis. J. Leukocyte Biol., 2004, 76, s. 300-306.
2. Swirnoff, A., Milbrandt, J.: DNA-binding specificity of NGFI-A and related zinc finger transcription factors. Mol. Cell. Biol., 1995, 15, s. 2275-2287.
3. Khachigian, L. M., Lindner, V., Williams, A. J., Collins, T.: Egr-1-induced endothelial gene expression: a common theme in vascular injury. Science, 1996, 271, s. 1427-1431.
4. Gimbrone, M. A.: Vascular endothelium, hemodynamic forces, and atherogenesis. Am. J. Pathol., 1999, 155, s. 1-5.
5. Khachigian, L. K., Collins, T.: Inducible expression of Egr-1-dependent genes. A paradigm of transcriptional activation in vascular endothelium. Circ. Res., 1997, 81, s. 457-461.
6. Huang, L. E., Bunn, H. F.: Hypoxia-inducible factor and its biomedical relevance. J. Biol. Chem., 2003, 278, s. 19575-19578.
7. Parsa, C. J., Kim, J., Riel, R. U. et al.: Cardioprotective effects of erythropoietin in the reperfused ischemic heart. A potential role for cardiac fibroblasts. J. Biol. Chem., 2004, 279, s. 20655-20662.
8. Karayiannakis, A. J., Zbar, A., Polychronidis, A., Simopoulos, C.: Serum and drainage fluid vascular endothelial growth factor levels in early surgical wounds. Eur. Surg. Res., 2003, 35, s. 492-496.
9. Schalch, P., Patejunas, G., Retuerto, M. A. et al.: Homozygous deletion of early growth response 1 gene and critical limb ischemia after vascular ligation in mice: evidence for a central role in vascular homeostasis. J. Thorac. Cardiovasc. Surg., 2004, 128, s. 595-601.
10. Sarateanu, C. S., Retuerto, M. A., Beckmann. J. T. et al.: An Egr-1 master switch for arteriogenesis: studies in Egr-1 homozygous negative and wild-type animals. J. Thorac. Cardiovasc. Surg., 2006, 131, s. 138-145.
11. Yan, S.-F., Lu, J., Xu, L. et al.: Pulmonary expression of early growth response-1: biphasic time course and effect of oxygen concentration. J. Appl. Physiol., 2000, 88, s. 2303-2309.
12. Landesberg, L. J., Ramalingam, R., Lee, K. et al.: Up-regulation of transcription factors in lung in the early phase of postpneumonectomy lung growth. Am. J. Physiol., 2001, 281,s. L1138-L1149.
13. Cui, M. Z., Penn, M. S., Chisolm, G. M.: Native and oxidized low density lipoprotein induction of tissue factor gene expression in smooth muscle cells is mediated by both Egr-1 and Sp1. J. Biol. Chem., 1999, 274, s. 32795-32802.
14. Stoyanova, E., Tesch, A., Armstrong, V. W., Wieland, E.: Enzymatically degraded low density lipoproteins are more potent inducers of egr-1 mRNA than oxidized or native low density lipoproteins. Clin. Biochem., 2001, 34, s. 483-490.
15. Takahashi, Y., Fujioka, Y., Takahashi, T. et al.: Chylomicron remnants regulate early growth response factor-1 in vascular smooth muscle cells. Life Sci., 2005, 77, s. 670-682.
16. Zhou, X.: CD4+ T cells in atherosclerosis. Biomed. Pharmacotherapy, 2003, 57, s. 287-291.
17. Thiel, C., Cibelli, G.: Regulation of life and death by the zinc finger transcription factor Egr-1. J. Cell. Physiol., 2002, 193, s. 287-292.
18. Fu, M., Zhu, X., Zhang, J. et al.: Egr-1 target genes in human endothelial cells identified by microarray analysis. Gene, 2003, 315, s.33-41.
19. Yan, S.-F., Fujita, T., Lu, J. et al.: Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat. Med., 2000, 6, s. 1355-1361.
20. Okada, M., Yan, S.-F., Pinsky, D. J.: Peroxisome proliferator-activated receptor-y (PPAR-y) activation suppresses ischemic induction of Egr-1 and its inflammatory gene targets. FASEB J., 2002, 16, s. 1861-1868.
21. Fu, M., Zhang, J., Lin, Y. et al.: Early growth response factor-1 is a critical transcriptional mediator of peroxisome proliferator-activated receptor-yl gene expression in human aortic smooth muscle cells. J. Biol. Chem., 2002, 277, s. 26808-26814.
22. Zhang, F., Lin, M., Abidi, P. et al.: Specific interaction of Egr-1 and c/EBPβ leads to the transcriptional activation of the human low density lipoprotein receptor gene. J. Biol. Chem., 2003, 278, s. 44246-44254.
23. Winn, R. K., Harlan, J. M.: The role of endothelial cell apoptosis in inflammatory and immune diseases. J. Thromb. Haemost., 2005, 3, s. 1815-1824.
24. Ju, S. T., Panka, D. J., Cui, H. et al.: Fas(CD95)/FasL interactions required for programmed cell death after T-cell activation. Nature, 1995, 373, s. 444-448.
25. Droin, N. M., Pinkoski, M. J., Dejardin, E., Green, D. R.: Egr family members regulate nonlymphoid expression of Fas ligand, TRAIL, and tumor necrosis factor during immune responses. Mol. Cell. Biol., 2003, 23, s. 7638-7647.
26. Yang, J., Jones, S. P., Suhara, T. et al.: Endothelial cell overexpression of Fas ligand attenuates ischemia-reperfusion injury in the heart. J. Biol. Chem., 2003, 278, s. 15185-15191.
27. Sata, M., Walsh, K.: TNF-α regulation of Fas ligand expression on the vascular endothelium modulates leukocyte extravasation. Nat. Med., 1998, 4, s. 415-420.
28. Sata, M., Walsh, K.: Endothelial cell apoptosis induced by oxidized LDL is associated with the down-regulation of the cellular caspase inhibitor FLIP. J. Biol. Chem., 1998, 273, s. 33103-33106.29.
29. Shimizu, M., Fukuo, K., Nagata, S. et al.: Increased plasma levels of the soluble form of Fas ligand in patients with acute myocardial infarction and unstable angina pectoris. J. Am. Coll. Cardiol., 2002, 39, s. 585-590.
30. Quinones, A., Dobberstein, K. U., Rainov, N. G.: The egr-1 gene is induced by DNA-damaging agents and non-genotoxic drugs in both normal and neoplastic human cells. Life Sci., 2003, 72, s. 2975-2992.
31. Nair, P., Muthukkumar, S., Sells, S. F. et al.: Early growth response-1-dependent apoptosis is mediated by p53. J. Biol. Chem., 1997, 272, s. 20131-20138.
32. Krones-Herzig, A., Adamson, E., Mercola, D.: Early growth response 1 protein, an upstream gatekeeper of the p53 tumor suppressor, controls replicative senescence. Proc. Natl. Acad. Sci. USA, 2003, 100, s. 3233-3238.
33. Rodríguez-Campos, A., Ruiz-Enríquez, P., Faraudo, S., Badimon, L.: Mitogen-induced p53 downregulation precedes vascular smooth muscle cell migration from healthy tunica media and proliferation. Arterioscler. Thromb. Vase. Biol., 2001, 21, s. 214-219.
34. Merched, A. J., Williams, E., Chan, L.: Macrophagespecific p53 expression plays a crucial role in atherosclerosis development and plaque remodeling. Arterioscler. Thromb. Vase. Biol., 2003, 23, s. 1608-1614.
35. Bennett, M. R., Littlewood, T. D., Schwartz, S. M., Weissberg, P. L.: Increased sensitivity to human vascular smooth muscle cells from atherosclerotic plaques to p53-mediated apoptosis. Circ. Res., 1997, 81, s. 591-599.
36. Rupp, J., Hellwig-Burgel, T., Wobbe, V. et al.: Chlamydia pneumoniae infection promotes a proliferative phenotype in the vasculature through Egr-1 activation in vitro and in vivo. Proc. Natl. Acad. Sci. USA, 2005, 102, s. 3447-3452.
37. Kamimura, M., Bea, F., Akizawa, T. et al.: Platelet-derived growth factor induces tissue factor expression in vascular smooth muscle cells via activation of Egr-1. Hypertension, 2004, 44, s. 944-951.
38. Haas, T. L., Stitelman, D., Davis, S. J. et al.: Egr-1 mediates extracellular matrix-driven transcription of membrane type 1 matrix metalloproteinase in endothelium. J. Biol. Chem., 1999, 274, s. 22679-22685.
39. Wada, Y., Fujimori, M., Suzuki, J. et al.: Egr-1 in vascular smooth muscle cell proliferation in response to allo-antigen. J. Surg. Res., 2003, 115, s. 294-302.
40. McCaffrey, T. A., Fu, C., Du, B. et al.: High-level expression of Egr-1 and Egr-1-inducible genes in mouse and human atherosclerosis. J. Clin. Invest., 2000, 105, s. 653-662.
41. Vidai, F., Aragonés, J., Alfranca, A., de Landázuri, M. O.: Up-regulation of vascular endothelial growth factor receptor Flt-1 after endothelial denudation: role of transcription factor Egr-1. Blood, 2000, 95, s. 3387-3395.
42. Du, B., Fu, C., Kent, C. et al.: Elevated Egr-1 in human atherosclerotic cells transcriptionally represses the transforming growth factor-β type II receptor. J. Biol. Chem., 2000, 275, 39039-39047.
43. Lutgens, E., Gijbels, M., Smook, M. et al.: Transforming growth factor-β mediates balance between inflammation and fibrosis during plaque progression. Arterioscler. Thromb. Vase. Biol., 2002, 22, s. 975-982.
44. Virmani, R., Kolodgie, F. D., Burke, A.P. et al.: Atherosclerotic plaque progression and vulnerability to rupture. Angiogenesis as a source of intraplaque hemorrhage. Arterioscler. Thromb. Vase. Biol., 2005, 25, s. 2054-2061.
45. Wu, S.-Q., Minami, T., Donovan, D. J., Aird, W. C.: The proximal serum response element in the Egr-1 promoter mediates response to thrombin in primary human endothelial cells. Blood, 2002, 100, s. 4454-4461.
46. Bea, F., Puolakkainen, M. H., McMillen, T. et al.: Chlamydia pneumoniae induces tissue factor expression in mouse macrophages via activation of Egr-1 and the MEK-ERK1/2 pathway. Circ. Res., 2003, 92, s. 394-401.
47. Akuzawa, N., Kurabayashi, M., Ohyama, Y. et al.: Zinc finger transcription factor Egr-1 activates Fit-1 gene expression in THP-1 cells on induction for macrophage differentiation. Arterioscler. Thromb. Vase. Biol., 2000, 20, s. 377-384.
48. Heeschen, C., Dimmeler, S., Hamm, C. W. et al. and CAPTURE Study Investigators: Serum level of the antiinflammatory cytokine interleukin-10 is an important prognostic determinant in patients with acute coronary syndromes. Circulation, 2003, 107, s. 2109-2114.
49. Kamimura, M., Viedt, C., Dalpke, A. et al.: Interleukin-10 suppresses tissue factor expression in lipopolysaccharidestimulated macrophages via inhibition of Egr-1 and a serum response element/MEK-ERKl/2 pathway. Circ. Res., 2005, 97, s. 305-313.
50. Bea, F., Blessing, E., Shelley, M. I. et al.: Simvastatin inhibits expression of tissue factor in advanced atherosclerotic lesions of apolipoprotein E deficient mice independently of lipid lowering: potential role of simvastatin-mediated inhibition of Egr-1 expression and activation. Atherosclerosis, 2003, 167, s. 187-194.